



(11) **EP 1 427 860 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
17.06.2009 Bulletin 2009/25

(21) Application number: **03738785.9**

(22) Date of filing: **03.07.2003**

(51) Int Cl.:
C12Q 1/68 (2006.01)

(86) International application number:
PCT/NL2003/000491

(87) International publication number:
WO 2003/080869 (02.10.2003 Gazette 2003/40)

(54) **STORING AND QUANTIFYING NUCLEIC ACID ADMINISTERED TO A SOLID CARRIER**

AUFBEWAHRUNG UND QUANTIFIZIERUNG VON AUF EINEN FESTEN TRAEGER
AUFGETRAGENEN NUKLEINSÄUREN

STOCKAGE ET QUANTIFICATION D'UN ACIDE NUCLEIQUE APPLIQUE SUR UN SUPPORT
SOLIDE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **04.07.2002 EP 02077697**

(43) Date of publication of application:
16.06.2004 Bulletin 2004/25

(60) Divisional application:
08151692.4

(73) Proprietor: **PrimaGen Holding B.V.**
1105 BA Amsterdam (NL)

(72) Inventors:
• **DE ROOIJ, Esther, Regina**
NL-3755 TC Eemnes (NL)
• **DE BAAR, Marinus, Petrus**
NL-3582 XP Utrecht (NL)

(74) Representative: **Winckels, Johannes Hubertus F.**
et al
Vereenigde
Johan de Wittlaan 7
2517 JR Den Haag (NL)

(56) References cited:
WO-A-98/23778 **US-A- 5 807 527**

- **CASSOL S A ET AL:** "Dried blood spots collected on filter paper: an international resource for the diagnosis and genetic characterization of human immunodeficiency virus type-1." **MEMORIAS DO INSTITUTO OSWALDO CRUZ. BRAZIL 1996 MAY-JUN, vol. 91, no. 3, May 1996 (1996-05), pages 351-358, XP002244891 ISSN: 0074-0276**
- **CASSOL S ET AL:** "Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper." **JOURNAL OF CLINICAL MICROBIOLOGY. UNITED STATES NOV 1997, vol. 35, no. 11, November 1997 (1997-11), pages 2795-2801, XP002244892 ISSN: 0095-1137**
- **NYAMBI P N ET AL:** "Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers." **JOURNAL OF CLINICAL MICROBIOLOGY. UNITED STATES NOV 1994, vol. 32, no. 11, November 1994 (1994-11), pages 2858-2860, XP008018434 ISSN: 0095-1137**
- **PHILLIPSS K ET AL:** "Detection of HIV-1 viral RNA from whole blood collected on filter paper." **ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND, vol. 41, 2001, page 354 XP008018436 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Illinois, USA; September 22-25, 2001, 2001**

EP 1 427 860 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- O'SHEA S ET AL: "Use of dried whole blood spots for quantification of HIV-1 RNA." AIDS (HAGERSTOWN), vol. 13, no. 5, 1 April 1999 (1999-04-01), pages 630-631, XP008018437 ISSN: 0269-9370
- MOYE J. ET AL: 'Detection and Quantitation of HIV-1 RNA from Filter Paper Adsorbed Whole Blood or Plasma by NASBA Isothermal Amplification' ABSTRACTS OF THE 4TH CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS 1997, WASHINGTON DC, page ABSTRACT 592 Retrieved from the Internet: <URL: www.retroconference.org/retrovirus97/abstracts/A592_abstract.htm> [retrieved on 2004-12-07]

Description

[0001] The invention relates to the field of medicine. More particularly the invention relates to diagnosis. The invention especially relates to quantification of a nucleic acid of interest in a sample.

[0002] Infections with pathogens are commonly observed all over the world. Such infections for instance include viral, bacterial, fungal and parasite infections. Early diagnosis of an infection is often preferred for efficient treatment, which can prevent severe pathological symptoms. Sometimes, early diagnosis is a prerequisite for a possibility of treatment, for extending a life-time and/or for improving the quality of life. Examples of such infections comprise Hepatitis C virus, Hepatitis B virus, tuberculosis, malaria and HIV, such as HIV-1.

[0003] The HIV-1 epidemic spreads readily over the world and with the spread of the virus the circulating subtypes of the HIV-1 virus are no longer restricted to one geographical place on earth. This development requires an application of (nucleic acid) diagnostic tests that can detect all subtypes of the HIV virus with equal accuracy and precision.

[0004] The globalization of the epidemic and especially the severity in resource-poor countries (sub-Saharan Africa and south-east Asia) has driven the developed world to assist the fighting of infection in the less-developed countries with access programs to pharmaceuticals. However, in order to efficiently help HIV-1 infected people in the less-developed world there has to be suitable diagnostics in place, for instance to monitor the efficacy of a treatment. Such suitable diagnostics are especially viral load assays that measure the amount of HIV-1 RNA in a bodily fluid, such as blood, blood plasma, mothers milk, semen, lymph fluid, sputum, liquor, saliva and/or urine of infected individuals. Likewise, suitable nucleic acid load assays are desired for other infection-related diseases.

[0005] The current status of suitable nucleic acid load assays is of such a high technical standard that these are not easily transferred to areas located at considerable distance of technological resources such as in sub-Saharan Africa and/or south-east Asia. This requires significant investment in infrastructure that is impossible in the setting of these regions. An alternative solution is an analysis of patient samples in laboratories in the developed world (for instance Europe and north America). This alternative is however impossible to exercise due to logistic problems. Body fluid samples such as blood or blood plasma samples of individuals have to be shipped to the laboratory in frozen conditions at temperatures well below 0°C, usually in a box with dry ice. This way of sending clinical material is very expensive and requires the availability of dry ice at the place of shipment. The latter is often not the case in countries of the less-developed world. Because of the costs and the unavailability of dry ice the remote testing of samples in laboratories ("service testing") is not an option for these countries and for infected people in these countries. The pharmaceutical access programs for less-developed countries can only be successful if diagnosis is optimized.

[0006] The invention provides a method for quantifying a nucleic acid of interest in at least one blood sample, comprising:

- administering said sample to a solid carrier capable of at least in part absorbing said sample, resulting in at least one spot;
- drying said carrier;
- excising at least one spot from said solid carrier, said at least one spot comprising at least 250 µl of sample;
- administering said at least one spot to a chaotropic nucleic acid isolation lysis buffer; so that nucleic acid is extracted from said carrier;
- further purifying the nucleic acid present in said lysis buffer;
- performing a nucleic acid amplification step; and
- quantifying said nucleic acid of interest.

[0007] With a method of the invention a sample, such as a body fluid sample, is stabilized in such a way that it can be shipped from the site of taking (for instance local hospital or lab in a less-developed country) and be sent to a service testing laboratory elsewhere in the world by normal logistics means, for instance normal postal service. Said method makes possible shipment of a dried sample via surface mail to a remote lab for detection of a nucleic acid of interest present in a sample.

[0008] A method of the invention can be performed with techniques known in the art. For instance, a defined amount of liquid sample can be administered to a solid carrier using a pipette. Said solid carrier is not critical and can comprise any solid carrier known in the art, as long as it is capable of at least in part absorbing said sample. For instance, said solid sample can comprise silica. Preferably, however, said solid carrier comprises filter paper. A filter paper is well capable of absorbing a liquid sample, while it is of light weight. This is very important for postal services. Said filter paper can comprise plain untreated filter paper like the 903 paper from Schleicher and Schuell, or treated filter paper that immobilizes nucleic acid for rapid purification. The two examples in the field are IsoCode paper from Schleicher and Schuell or FTA-treated paper from Whatman, which both are bactericidal, fungicidal and virucidal, inhibits the growth of bacteria and fungi and kills viruses that come in contact with the matrix, allowing for safe sample handling and sample stability. Another example of a suitable carrier to store and transport dried fluid samples is a device designed by Lifestock (US 5139742) This device contains a small knife with a capillary tube directly attached to it, which enables collection,

storage and transportation of blood that dries in the capillary tube thereby comparable to the method with the filter paper.

[0009] Said carrier can be dried by different techniques known in the art. Preferably said sample is dried to the air. This is inexpensive and effective.

5 **[0010]** By a representative part of a carrier is meant a part which is indicative for the amount of sample administered to said solid carrier. For instance said representative part can comprise the whole of said sample. Said representative part can also comprise half the amount of said sample. In that case the other half can be used to perform a second experiment. Said second experiment can be a different experiment, or can be a similar experiment. In the latter case a certain result can be obtained *in duplo*, which is more accurate.

10 **[0011]** By a representative amount of nucleic acid is meant an amount which is indicative for the amount of nucleic acid present in said sample. Said representative amount can comprise the whole amount of said nucleic acid present in said sample. Alternatively, said representative amount can comprise a part of said nucleic acid present in said sample.

15 **[0012]** A method of the invention is provided wherein at least 250 μ l of sample is administered to said carrier. More preferably at least 500 μ l of sample is administered to said carrier. With a high sample volume, low titers of nucleic acid of interest can still be detected. A major drawback in current detection methods is that only nucleic acid with a concentration above a certain threshold value can be detected. This means that infected individuals with a low load of pathogenic nucleic acid are not diagnosed as being infected and, hence, do not get treatment at an appropriate early timepoint. Until the present invention high amounts of body fluid samples, such as blood or plasma samples, were not suitable for testing because inhibitory effects were observed. For instance, it has been reported that hemoglobin and carbonic anhydrase present in whole blood interfere with the polymerase chain reaction (4). PCR mixtures became deep brown because of the elution of heme and its degradation products from filter blotters (5). To improve a PCR amplification, specimens were treated with methanol before the PCR reaction (6). This involves an extra step, with risk of contaminations and less reliable test results. Besides, chelating metal ions are reported to act as catalysts for the breakdown of DNA at a high temperature with low ionic strength (7).

25 **[0013]** Surprisingly, with a method of the invention high amounts of sample can be stored on a dried solid carrier and subsequently analysed. None of the above-mentioned inhibitory effects are observed and treatment with methanol as a precautionary measure is not necessary. With a method of the invention it is now possible to analyse large samples for the presence of a nucleic acid of interest. Hence, low concentrations of a nucleic acid of interest in a sample can now be detected. A method of the invention is suitable for screening individuals for the presence of one or more specific pathogens, such as HIV-1. Alternatively an individual suffering from a disease, or at risk of suffering from a disease, can be investigated with a method of the invention. Once one or more foreign nucleic acid(s) are found, it can be determined to which kind of microorganism it belongs. This can for instance be done by hybridisation protocols using different kinds of probes. Alternatively, techniques to determine the sequence of the nucleic acid and analyzing this sequence for homology with any known sequences can be performed. In one embodiment the invention therefore provides a method of the invention, comprising identifying said nucleic acid of interest.

35 **[0014]** A method of the invention is provided wherein said nucleic acid is quantified. Surprisingly it is not only possible with a method of the invention to detect a nucleic acid of interest, but also to determine the amount of said nucleic acid present in said sample. With a method of the invention no significant amount of nucleic acid is lost/broken down during storage and/or during the isolation and/or detection procedure. In the example is shown that, if a method of the invention is used, a measured amount of a nucleic acid of interest from a dried sample stored on a solid carrier is comparable to the measured amount of said nucleic acid of interest when said sample is directly subjected to analysis.

40 **[0015]** Dried samples on a solid carrier can now be investigated for the amount of pathogenic nucleic acid present. Hence, not only the presence, but also the stage of a disease can now be determined. It is now possible to diagnose individuals of regions with insufficient facilities, such as inhabitants from resource-poor countries. A body fluid sample, such as a blood sample, can be collected on a solid carrier such as a filter paper. Said filter paper can be sent to a laboratory, for instance in Western Europe. Subsequently the amount of a nucleic acid of interest can be determined and, hence, the status of a disease. It can also be determined whether a treatment is effective by determining whether the amount of said nucleic acid declines over time.

45 **[0016]** In one aspect the invention provides a method of the invention wherein said solid carrier is provided with at least two samples. Preferably, said samples are obtained from the same individual. More preferably, said samples are obtained from the same body fluid of said individual. Said samples can for instance comprise two aliquots of blood. Each of said blood samples can be tested independently by a method of the invention. This way the presence and/or the amount of a nucleic acid of interest in the blood of said individual can be tested *in duplo*. This results in more accurate results. Moreover, each sample can be tested by different persons/different institutes. Errors made by individuals and/or errors because of unreliable equipment can be revealed by an independent second measurement.

55 **[0017]** In an alternative embodiment, said two samples are used for different purposes. For instance, one sample can be tested for the amount of viral nucleic acid, while the other sample can be tested for the amount of bacterial nucleic acid. Both samples can be used to obtain ratios between viral nucleic acid and chromosomal DNA (as is important for CMV), or for ratio between mitochondrial vs cellular DNA/RNA or to determine ratios involving mRNA's or ribosomal

RNA's. Many of these tests, however can also be carried out using only one sample.

[0018] In one embodiment, said solid carrier comprises a series of at least two samples, taken at different time points. This way a course of a disease can be followed over time. This embodiment is also particularly suitable for determining whether a treatment is effective. For instance, a sample can be administered to said solid carrier at the start of a treatment, and at regular interval afterwards. In this way the said solid carrier does not only serve the purpose of transportation device, but also for stable storage at ambient temperatures without degradation of the nucleic acid of interest. Such solid carrier can be sent to a suitable institute after a certain amount of time. It can then be established whether a treatment is efficient by quantifying the amount of pathogenic nucleic acid in each sample by a method of the invention. It can be established whether said amount declines over time.

[0019] Likewise, samples can be taken from a diseased individual at regular intervals. The amount of pathogenic nucleic acid in each sample can subsequently be quantified. This provides more insight into the course of said disease; for instance whether the amount of pathogenic nucleic acid increases over time, etc.

[0020] It is not necessary to send each sample separately to said institute. A number of them can be collected over time and be sent at once. This saves time and money. Moreover, because said samples are sent together, no storing and sorting of separately sent samples is necessary. A risk of samples getting lost is decreased.

[0021] To even more accurately quantify an amount of a nucleic acid of interest with a method of the invention, a known amount of a reference nucleic acid can be administered to said solid carrier. Said reference nucleic acid can be quantified, as well as a nucleic acid of interest. The accuracy of a quantification of a nucleic acid of interest can be determined by comparing a measured amount of said reference nucleic acid with the administered amount of said reference nucleic acid. If said measured amount differs slightly from the administered amount, the same is likely to be true for said nucleic acid of interest. Hence, a measured amount of said nucleic acid of interest can be corrected to obtain an even more accurate result.

[0022] Moreover, with a reference nucleic acid a representative part comprising a part of a sample can be determined. If a representative part comprising a part of said sample is provided to said nucleic acid isolation buffer, and the measured amount of reference nucleic acid appears to be one third of the administered amount, it indicates that the measured amount of a nucleic acid of interest is also approximately one third of the amount present in said sample. Hence, a reference nucleic acid shows with which factor a measured amount of nucleic acid of the invention should be multiplied if a part of said sample is provided to said nucleic acid isolation buffer. A reference nucleic acid is preferred which spreads along said solid carrier essentially the same way as said nucleic acid of interest. In that case it makes no significant difference which part of said solid carrier is used in a method of the invention. Another way of accurately quantification of the nucleic acid of interest is by relating it to the amount of other nucleic acids. In this way it is possible, in either the same reaction or in separate reactions, in either the same sample or one of the other samples, to establish a ratio between any DNA and DNA, any RNA and DNA or vice-versa, and any RNA and RNA target. The invention could comprise applications to determine the ratio between nucleic acids from the host, e.g. the amount of mitochondrial DNA versus nuclear DNA as a measure of response to certain HIV therapy, or between nucleic acids from a pathogen versus those from the host, e.g. the amount of CMV DNA versus host nuclear DNA. Other applications could comprise the amount of mRNA per cell within the field of gene expression profiling.

[0023] The invention also provides a method of the invention wherein said representative part comprises essentially the whole of said at least one sample. It is shown by the present inventors that even with a large sample a reliable detection and/or quantification of a nucleic acid of interest is possible with a method of the invention. If the whole of a large sample is used, even low concentrations of nucleic acid can be detected and quantified.

[0024] A representative part of said carrier can be provided by cutting a visible spot out of a solid carrier such as filter paper. This cutting can be done using a normal pair of scissors, but can also be completely automated, e.g. using equipment from Wallack to punch out equal surfaces of the solid carrier. Another way of easing this type of punching by hand, would be to pre-punch said solid carrier, after which the sample is applied and dried. At arrival in the laboratory for analysis, this pre-punched part can be easily punched out completely by either specially designed devices or existing devices as a Safe-lock tube from Eppendorf. Also a representative part of said spot can be used. However, it is preferred to use the whole carrier, as it is then ensured that the whole sample is measured. According to the present invention, a solid carrier such as filter paper does not significantly influence a detection and/or quantification of a nucleic acid of interest. Therefore, a method of the invention is preferred wherein said representative part comprises essentially the whole of said solid carrier.

[0025] If in a method of the invention said solid carrier is provided with at least two samples, said representative part preferably comprises one of said samples. Said representative part can be used for detecting and/or quantifying a nucleic acid of interest. As has been explained above, a representative part comprising said second sample can be used for a measurement *in duplo*. Alternatively, an other measurement can be performed.

[0026] A method of the invention is provided wherein said nucleic acid isolation solution comprises a chaotropic nucleic acid isolation lysis buffer. More preferably, a nucleic acid isolation buffer as described by Boom et al is used. Preferably said solid carrier comprises filter paper, since filter paper is cheap, well capable of absorbing a liquid sample and of light

weight which facilitates transport. Typically, elution of the said nucleic acid takes at least 30 minutes at room-temperature or even shorter at elevated temperatures, whereas nucleic acid from a bodily fluid that is applied directly to the lysis buffer is typically released within 10 minutes. Elevated temperatures will facilitate efficient and quick elution of the nucleic acid from the solid carrier.

5 **[0027]** A method of the invention is particularly suitable for quantifying viral nucleic acid, especially retroviral nucleic acid. Viral nucleic acid can be present in a latent stage, which can last for a considerable time. Moreover, a virus such as HIV, HTLV and HHV is often present during a considerable time within an individual before said individual experiences any significant symptoms. During that time said virus is often already transmittable to other persons. Moreover, treatment in an early stage can improve a chance of recovery, prolong a life-time and/or improve the quality of life. Therefore it is particularly important to check an individual for the presence of viral nucleic acid with a method of the invention. Viral nucleic acids to be detected include sequences from Hepatitis A, B, C, parvovirus, etc. Preferably, said viral nucleic acid comprises HIV and/or HTLV. More preferably, said viral nucleic acid comprises HIV-1.

10 **[0028]** In one embodiment a method of the invention is provided, wherein said method comprises genotyping a mutant. This is especially useful for organisms with a fast-changing genome, such as (retro)viruses. Genotyping is for instance useful for determining whether a certain treatment is likely to be suitable for an individual patient. Moreover, if a new mutant is found, an existing pharmaceutical preparation can be adapted, or a new medicament can be developed.

15 **[0029]** A method of the invention is particularly suitable for quantifying a nucleic acid of interest in a body fluid, such as blood. A sample of such body fluid is easy to obtain. Obtaining such sample does not cause much inconvenience to an individual, which would be the case if for instance a biopsy were taken. Moreover, obtaining a body fluid sample does not require special equipment, which is often lacking in less developed countries and in remote areas. Preferably a method of the invention is provided wherein said sample comprises a droplet of whole blood from a finger or heel puncture. Such finger or heel puncture is commonly taken from newborns, so that said material is often available without further bothering the individuals. A plasma sample allows more accurate measurement of an amount of free virus particles, whereas for instance a blood sample also includes viral nucleic acid integrated within cells.

20 **[0030]** To make sure that at least the minimally necessary amount of bodily fluids is collected, a pre-determined surface can be printed or applied in any other way to the solid carrier. The meaning is that the surface will be completely filled with the requested bodily fluid.

25 **[0031]** For detection of a nucleic acid of interest often an amplification step (such as PCR or NASBA) is necessary. Amplified nucleic acid can subsequently be detected using known methods in the art. A method of the invention therefore comprises an amplification step. Preferably said amplification comprises real-time monitored amplification. Produced nucleic acid is directly made visible during such amplification reaction. This can for instance be achieved by molecular beacon probes or other types of probes. Once these probes anneal to a template, a fluorescence signal can be generated which can be monitored during an amplification reaction. The intensity of fluorescence is indicative for the amount of nucleic acid generated. A calibration curve can be created using known amounts of nucleic acid. A fluorescence signal from a sample with an unknown amount of nucleic acid can then be compared with said calibration curve. This way the amount of said nucleic acid in said sample can be determined, because the intensity of fluorescence and the amount of nucleic acid are correlated.

30 **[0032]** In another embodiment said nucleic acid quantification is performed with an end-point read-out system. Such systems for instance comprises a colorimetric detection, an enzymatic assay, and/or a dipstick.

35 **[0033]** The invention also provides a use of a dried solid carrier provided with a sample for detecting, identifying and/or quantifying a nucleic acid of interest in said sample. As has been described previously, said dried solid carrier can be stored and transported easily, after which reliable nucleic acid detection and quantification can be carried out. Preferably said solid carrier comprises at least 250 μ l, more preferably at least 500 μ l of blood in a dried form. With a use of the invention a large volume of sample can be investigated, allowing detection and/or quantification of a low concentration of nucleic acid. The way the solid carrier is designed, it could well contain the carrier itself that can absorb the bodily fluid, linked to a part of paper or surface on which information can be written or printed, e.g. information about the patient, date of sampling or more dates of sampling, therapy regimen, barcodes, ID-numbers, etc. Such a surface specifically for this type of information is unequivocally linked to the carrier with sample, thereby making sure the information is not lost. Typically this type of surfaces can contain much more information than a tube can hold. Logically, any variation on this theme is possible.

40 **[0034]** The invention also uses a kit of parts for detecting, identifying and/or quantifying a nucleic acid of interest in a sample, comprising:

- 45 - a solid carrier capable of at least in part absorbing said sample; and
- 50 - a nucleic acid isolation solution.

[0035] Preferably said kit further comprises means for nucleic acid amplification. Said means for instance comprise means for real-time monitored amplification, and/or means for amplification with end-point detection/quantification. Such

kit of parts is for instance useful in resource-poor countries with a few hospitals. Such hospitals can distribute said solid carriers, such as filter papers, among inhabitants in remote areas. Once samples have been collected, they can be stored and transported to such hospitals. If said hospital is properly equipped, said samples can be investigated using said nucleic acid isolation solution. Of course, also hospitals in developed countries can use such kit of part for collecting and testing a sample. A kit of parts for detection, identification and/or quantification could well contain a collection of materials necessary to safely draw the bodily fluid from the patient. Logically with external bodily fluids like urine, mothers milk or saliva, other safety precautions will have to be taken than when internal bodily fluids are samples like blood, plasma, serum, or lymph drain. For the internal bodily fluids, one can compose a kit that contains a solid carrier capable of at least in part absorbing said sample, and a nucleic acid isolation solution, next to a pair of examination gloves, a alcohol swab to clean the skin, a finger or heel puncture device, a bandage, an envelope e.g. with the address of the destined laboratory as well as with a space for an identification number or patient code, and coated inside for safe postal transportation, and a desiccator to keep the sample dry and to prevent it from fungal or bacterial growth. Other possibilities for the collection device could comprise of specially designed devices for one-time use, like a device described in patent number US5139742: Disposable liquid testing device by Livestock Control Holding B.V. in Amersfoort, the Netherlands. Any combination of these items, or replaced for other type of items/devices to be used for storage and/or transportation of any nucleic acid containing bodily fluids is possible.

[0036] A solid carrier comprising at least the equivalent of 500 μ l of blood or a derivative thereof in dried form is also used. Preferably, said solid carrier comprises at least two samples. If said samples are of the same kind, said samples can both be tested separately, resulting in an *in duplo* test. Furthermore, a result of a first test can be controlled by independently testing the other sample. Alternatively, said samples are used for different purposes.

[0037] A solid carrier comprising a series of samples obtained at different data is also used. As has been described before, such solid carrier is suitable for following a course of a disease over time, and/or for testing whether a certain treatment is effective. Preferably a solid carrier comprises a known amount of a reference nucleic acid.

[0038] The invention is further explained in the following example. The example only serves to clarify the invention. It does not limit the scope of the invention in any way. Alternative embodiments are also within the scope of the present invention.

Examples

Example 1

[0039] Blood and blood plasma were spotted in 50 μ l droplets on S&S 903 paper (Schleicher & Schull) and dried in the air. Simultaneously, 200 μ l of the same blood and plasma samples were directly added to the lysis buffer as described by Boom et al. (1990). After drying, the spots on the filter paper were kept at ambient temperature for up to 3 weeks and can probably be kept at ambient temperature for months. The spots on the filter paper were excised with a normal pair of scissors and administered to a tube containing lysis buffer as described by Boom et al. (1990). The filter spots of 50 μ l blood or plasma were added to three different tubes: 1) a 50 ml tube containing 9 ml lysis buffer, 2) a 15 ml tube containing 15 ml lysis buffer or 3) a 1.5 ml eppendorf tube containing 1 ml lysis buffer.

[0040] The tubes were mildly shaken on a shaking platform for 3 hours at ambient temperature. During this incubation the blood or plasma spot dissolves from the filter paper into the lysis buffer. Subsequently the filters were removed from the tubes with a cleaned pair of tweezers. Between tubes the tweezers were subsequently cleaned with hot water-chlorine-hot water-70% alcohol.

[0041] To the tubes with lysis buffer and the samples a 1.10^6 copies of a system control RNA molecule were added to allow identification of false negative reactions at a later stage. The system control RNA is amplified with the same primers as the wild-type HIV-1 and detected with a distinguishable probe in the reaction. Due to a length difference the system control RNA can only be amplified and detected in the absence (or very low amounts) of the wild-type HIV-1 RNA.

[0042] The nucleic acid now present in the lysis buffer was further purified with the method described by Boom et al (1990) or with dedicated isolation kits purchased from Qiagen (Qiagen GmbH, Max Volmer Strasse 4, 40724 Hilden, Germany) or Biomerieux (formerly Organon Teknika, Boseind 15, 5281 RM Boxtel, The Netherlands) and used according to the manufacturer's protocols. The isolated nucleic acid was stored at -80°C until further analysis. Usually 5 μ l was used as input in NASBA amplification reactions determining the amount of HIV-1 RNA as described by De Baar et al. (1, 2)

[0043] Standard NASBA nucleic acid amplification reactions were performed in a 20 μ l reaction volume and contained: 40mM Tris-pH 8.5, 70mM KCl, 12mM MgCl₂, 5mM dithiothreitol, 1mM dNTP's (each), 2mM rNTP's (each), 0.2 μ M primer (each), (P1: AAT TCT AAT ACG ACT CAC TAT AGG GAG AGG GGC GCC ACT GCT AGA GA and P2: CTC AAT AAA GCT TGC CTT GA), 0,05 μ M molecular beacon for the wild-type HIV-1 sequence (MB045: FAM-CGA CGT AGT AGT GTG TGC CCG TCT GTA CGT CG-dabcyl), 0.05 μ M molecular beacon for the system control RNA (MB054: ROX-CCG ACT CTC TAC ACA CCA GAC AAA AAA CGA GTC GG-dabcyl) 0.05 μ M molecular beacon for the wild-type HIV-1 sequence, 0.05 μ M molecular beacon for the system control RNA, 375mM sorbitol, 0.105 μ g/ μ l bovine serum albumin,

EP 1 427 860 B1

6.4 units AMV RT, 32 units T7 RNA polymerase, 0.08 units RNase H and input nucleic acid. The complete mixture, except the enzymes was, prior to adding the enzymes, heated to 65°C in order to denature any secondary structure in the RNA and to allow the primers to anneal. After cooling the mixture to 41°C the enzymes were added. The amplification took place at 41°C for 90 min in a thermostated fluorimeter (CytoFluor 2000 or EasyQ Reader) and the fluorescent signal of the molecular beacon probe was measured every minute.

[0044] To achieve quantification, a dilution series of target sequence for a particular primer set was amplified and the time points at which the reactions became positive (the time to positivity, TTP) were plotted against the input amounts of nucleic acid. This way a calibration curve was created that could be used to read TTP values of reactions with unknown amounts of input and deduce the input amount.

[0045] The results of the determinations in example 1 are shown in table 1 below. By the results of the system control RNA is appeared that there were no false negative results and all negative data reported in table 1 are true negative data resulting from the absence of HIV-1 sequence or presence at concentrations below the detection limit of the tests.

Patient A	# 200µl plasma direct to lysis buffer	200µl blood direct to lysis buffer ^B	50 µl plasma spotted ^B	200 µl plasma spotted ^A	50 µl blood spotted ^B	200 µl blood spotted ^A
R02-05195	Neg.	Pos.	Neg.	Neg.	Neg.	LQL
R02-05260	Neg.	Neg.	Neg.	Neg.	Neg.	Neg.
R02-05179	3.84	Pos.	Pos.	3.86	Pos.	3.86
R02-05183	LQL.	Pos.	Pos.	3.74	Pos.	LQL
R02-05240	3.79	Pos.	Pos.	3.86	Pos.	3.77
R02-05244	3.79	Pos.	Pos.	3.59	Pos.	LQL
R02-05265	3.20	Pos.	Neg.	LQL	Pos.	LQL
R02-05175	5.18	Pos.	Pos.	4.79	Pos.	4.76
<p>A. The results were determined quantitatively as described in the text with TTP measurements. The results are given as the Log number. Neg. indicates a negative result, LQL indicates a positive result, but too low for accurate quantification</p> <p>B. The determinations of 200 µl blood direct to lysis buffer, 50 µl plasma spotted and 50 µl blood spotted were not performed quantitatively, only qualitative with either a positive (Pos.) or negative (Neg.) result.</p>						

[0046] The data in table 1 clearly indicate a good correlation between the results obtained with the direct admission of sample to the lysis buffer compared to first spotting of the sample on paper, drying and thereafter admission to the lysis buffer.

Example 2

[0047] Mother milk of 1 woman, spiked with virus from 6 different isolates in 4 concentrations was spotted in 4 times 50 µl droplets on S&S 903 paper (Schleicher & Schuell), dried on the air and stored for a minimum of one week at ambient temperature. After drying, the spots on the filter paper were kept at ambient temperature for up to 3 weeks and can probably be kept at ambient temperature for months. Simultaneously, 200 µl of the same mother milk samples was directly added to the lysis buffer as described by Boom et al. (1990). The spots on the filter paper were excised with a normal pair of scissors and administered to a tube containing 4 ml lysis buffer as described by Boom et al. (1990).

[0048] The tubes were mildly shaken on a shaking platform overnight at ambient temperature. During this incubation the dried spot dissolves from the filter paper into the lysis buffer. Subsequently the filters were removed from the tubes with a cleaned pair of tweezers. Between tubes the tweezers were subsequently cleaned with chlorine-hot water-70% alcohol.

[0049] To the tubes with lysis buffer and sample 1.000.000 copies of a system control RNA molecule was added to allow identification of false negative reactions at a later stage. The system control RNA is amplified with the same primers as the wild-type HIV-1 and detected with a distinguishable probe in the reaction. Due to a length difference the system

EP 1 427 860 B1

control RNA can only be amplified and detected in the absence (or very low amounts) of the wild-type HIV-1 RNA. The nucleic acid now present in the lysis buffer was further purified with the method described by Boom et al (1990) or with dedicated isolation kits purchased from Qiagen (Qiagen GmbH, Max Volmer Strasse 4, 40724 Hilden, Germany) or Biomerieux (formerly Organon Teknika, Boseind 15, 5281 RM Boxtel, The Netherlands) and used according to the manufacturer's protocols. The isolated nucleic acid was stored at -80°C until further analysis. Usually 5 µl was used as input in NASBA amplification reactions determining the amount of HIV-1 RNA as described by De Baar et al.

[0050] Standard NASBA nucleic acid amplification reactions were performed in a 20µl reaction volume and contained: 40mM Tris-pH 8.5, 70mM KCl, 12mM MgCl₂, 5mM dithiothreitol, 1mM dNTP's (each), 2mM rNTP's (each), 0.2µM primer (each) (P1: AAT TCT AAT ACG ACT CAC TAT AGG GAG AGG GGC GCC ACT GCT AGA GA and P2: CTC AAT AAA GCT TGC CTT GA), 0.05µM molecular beacon for the wild-type HIV-1 sequence (MB045: FAM-CGA CGT AGT AGT GTG TGC CCG TCT GTA CGT CG-dabcyl), 0.05µM molecular beacon for the system control RNA (MB054: ROX-CCG ACT CTC TAC ACA CCA GAC AAA AAA CGA GTC GG-dabcyl), 375mM sorbitol, 0.105 µg/µl bovine serum albumin, 6.4 units AMV RT, 32 units T7 RNA polymerase, 0.08 units RNase H and input nucleic acid. The complete mixture, except the enzymes was, prior to adding the enzymes, heated to 65°C in order to denature any secondary structure in the RNA and to allow the primers to anneal. After cooling the mixture to 41°C the enzymes were added. The amplification took place at 41°C for 60 min in a thermostated fluorimeter (CytoFluor 2000 or EasyQ Reader) and the fluorescent signal of the molecular beacon probe was measured every minute.

[0051] To achieve quantification, a dilution series of target sequence for a particular primer set was amplified and the time points at which the reactions became positive (the time to positivity, TTP) were plotted against the input amounts of nucleic acid. This way a calibration curve was created that could be used to read TTP values of reactions with unknown amounts of input and deduce the input amount.

[0052] The results of the determinations of the same samples spotted and added directly to the lysis buffer were compared and the analysis is shown in figure 1 below. By the results of the system control RNA it appeared that there were no false negative results and all negative data reported in figure 1 are true negative data resulting from the absence of HIV-1 sequence or presence at concentrations below the detection limit of the tests.

Example 3

[0053] Plasma of 88 HIV-1 infected individuals was spotted in 200 µl droplets on S&S 903 paper (Schleiger & Schull) and dried in the air and stored for a minimum of 24 hours at ambient temperature. Simultaneously, 200 µl of the same plasma samples was directly added to the lysis buffer as described by Boom et al. (1990). The spots on the filter paper were pinched out and administered to a tube containing 4 ml lysis buffer as described by Boom et al. (1990).

[0054] The tubes were mildly shaken on a shaking platform for 3 hours at ambient temperature. During this incubation the dried spot dissolves from the filter paper into the lysis buffer. Subsequently the filters were removed from the tubes with a cleaned pair of tweezers. Between tubes the tweezers were subsequently cleaned with hot water-chlorine-hot water-70% alcohol.

[0055] The nucleic acid now present in the lysis buffer was further purified with the method described by Boom et al (1990) or with dedicated isolation kits purchased from Qiagen (Qiagen GmbH, Max Volmer Strasse 4, 40724 Hilden, Germany) or Biomerieux (formerly Organon Teknika, Boseind 15, 5281 RM Boxtel, The Netherlands) and used according to the manufacturer's protocols. The isolated nucleic acid was stored at -80°C until further analysis. Usually 5 µl was used as input in NASBA amplification reactions determining the amount of HIV-1 RNA as described by De Baar et al [2,3].

[0056] Standard NASBA nucleic acid amplification reactions were performed in a 20µl reaction volume and contained: 40mM Tris-pH 8.5, 70mM KCl, 12mM MgCl₂, 5mM dithiothreitol, 1mM dNTP's (each), 2mM rNTP's (each), 0.2µM primer (each), 0.05µM molecular beacon for the wild-type HIV-1 sequence, 0.05µM molecular beacon for the system control RNA, 375mM sorbitol, 0.105 µg/µl bovine serum albumin, 6.4 units AMV RT, 32 units T7 RNA polymerase, 0.08 units RNase H and input nucleic acid. The complete mixture, except the enzymes was, prior to adding the enzymes, heated to 65°C in order to denature any secondary structure in the RNA and to allow the primers to anneal. After cooling the mixture to 41°C the enzymes were added. The amplification took place at 41°C for 90 min in a thermostated fluorimeter (CytoFluor 2000 or EasyQ Reader) and the fluorescent signal of the molecular beacon probe was measured every minute.

[0057] To achieve quantification, a dilution series of target sequence for a particular primer set was amplified and the time points at which the reactions became positive (the time to positivity, TTP) were plotted against the input amounts of nucleic acid. This way a calibration curve was created that could be used to read TTP values of reactions with unknown amounts of input and deduce the input amount.

[0058] The results of the determinations of the same samples spotted and added directly to the lysis buffer were compared and the analysis is shown in figure 2.

[0059] The data in figure 2 clearly indicate a very good correlation between the results obtained with the direct admission of sample to the lysis buffer compared to first spotting of the sample on paper, drying and thereafter admission to the lysis buffer. When analyzed with the Pearson correlation test a correlation coefficient (r) of 0.919 for plasma direct and

0.959 for dried plasma was found.

Figure legends

5 [0060]

Figure 1. Comparison of quantitative HIV-1 data obtained on mother milk samples that were analyzed directly or were first spotted and dried on filter paper. The assay cut off is at log₂, indicated by solid lines in the graph. The numbers on the axis indicates the log copy number of HIV-1 RNA molecules found in the test.

10 The data in figure 1 clearly indicate a very good correlation between the results obtained with the direct admission of sample to the lysis buffer compared to first spotting of the sample on paper, drying and thereafter admission to the lysis buffer.

15 **Figure 2.** Comparison of quantitative HIV-1 data obtained on plasma samples that were analyzed directly or were first spotted and dried on filter paper. The assay lower limit of detection is at log₂, indicated by solid lines in the graph. The numbers on the axis indicates the log copy number of HIV-1 RNA molecules found in the test.

References

20 [0061]

1. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J, 1990. Rapid and simple method for purification of nucleic acids. *J Clin Microbiol*; 28(3):495-503.

25 2. de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J, de Ronde A. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. *J Clin Microbiol*. 2001 Apr;39(4):1378-84.

30 3. de Baar MP, Timmermans EC, Bakker M, de Rooij E, van Gemen B, Goudsmit J. One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. *J Clin Microbiol*. 2001 May;39(5):1895-902.

35 4. Caggana M, Conroy J, Pass K. Rapid, efficient method for multiplex amplification from filter paper. *Human mutation* 1998; 11: 404-409.

5. Romppanen E, Mononen I. PCR-oligonucleotide ligation assay from dried blood spots. *Clinical Chemistry* 1999; 45(11): 2022-2025.

40 6. Romppanen E. Oligonucleotide ligation assay: applications to molecular diagnosis of inherited disorders. *Scand J Clin Lab Invest* 2001; 61: 123-130.

7. Tzeng CC, Lin SJ, Chen YJ, Kuo PL, Jong YJ, Tsai LP, Chen RM. An effective strategy of using molecular testing to screen mentally retarded individuals for fragile X syndrome. *Diagnostic Molecular Pathology* 2001; 10: 34-40.

45

Claims

1. A method for quantifying a nucleic acid of interest in at least one blood sample, comprising:

- 50 - administering said sample to a solid carrier capable of at least in part absorbing said sample, resulting in at least one spot;
- drying said carrier;
- excising at least one spot from said solid carrier, said at least one spot comprising at least 250 μ l of sample;
- 55 - administering said at least one spot to a chaotropic nucleic acid isolation lysis buffer; so that nucleic acid is extracted from said carrier;
- further purifying the nucleic acid present in said lysis buffer;
- performing a nucleic acid amplification step; and
- quantifying said nucleic acid of interest.

EP 1 427 860 B1

2. A method according to claim 1 comprising identifying said nucleic acid.
3. A method according to any one of claims 1-2, wherein said solid carrier is provided with at least two samples.
- 5 4. A method according to any one of claims 1-3, comprising administering to said solid carrier a known amount of a reference nucleic acid.
5. A method according to any one of claims 1-4, wherein said part comprises the whole of said at least one sample.
- 10 6. A method according to claim 3 or 4, wherein said part comprises one of said samples.
7. A method according to any one of claims 1-6, wherein said nucleic acid comprises RNA.
8. A method according to claim 7 wherein said RNA comprises mitochondrial RNA, viral RNA and/or messenger RNA.
- 15 9. A method according to any one of claims 1-8, wherein viral nucleic acid is detected.
10. A method according to claim 9, wherein said viral nucleic acid comprises a retroviral nucleic acid.
- 20 11. A method according to claim 9 or 10, wherein said viral nucleic acid comprises HIV and/or HTLV.
12. A method according to any one of claims 9-11, wherein said viral nucleic acid comprises HIV-1.
13. A method according to any one of claims 1-12, wherein said carrier comprises a filter-paper.
- 25 14. A method according to any one of claim 1-13, comprising genotyping a mutant.
15. A method according to any one of claims 1-14, wherein said sample comprises a droplet of whole blood from a finger or heel puncture.
- 30 16. A method according to claim 15, wherein said amplification comprises real-time monitored amplification.
17. A method according to any one of claims 1-16, wherein said nucleic acid detection and/or quantification is performed with an end-point read-out system.
- 35 18. A method according to any one of claims 1-17 wherein a ratio between different nucleic acids is determined.

Patentansprüche

- 40 1. Verfahren zur Quantifizierung einer Nucleinsäure von Interesse in wenigstens einer Blutprobe, umfassend:
 - Zufügen der Probe zu einem festen Träger, der fähig ist, wenigstens teilweise die Probe zu absorbieren, was in wenigstens einem Fleck resultiert;
 - 45 - Trocknen des Trägers;
 - Ausschneiden wenigstens eines Flecks aus dem festen Träger, wobei wenigstens ein Fleck wenigstens 250 µl Probe umfasst;
 - Zufügen des wenigstens einen Flecks zu einem chaotropen Nucleinsäure-Isolierungslysepuffer, so dass die Nucleinsäure aus dem Träger extrahiert wird;
 - 50 - weitere Reinigung der Nucleinsäure, die in dem Lysepuffer vorliegt;
 - Durchführen eines Nucleinsäure-Amplifikations-Schritts; und
 - Quantifizieren der Nucleinsäure von Interesse.
- 55 2. Verfahren gemäß Anspruch 1, das ein Identifizieren der Nucleinsäure umfasst.
3. Verfahren gemäß einem der Ansprüche 1 bis 2, wobei der feste Träger mit wenigstens zwei Proben versehen wird.
4. Verfahren gemäß einem der Ansprüche 1 bis 3, umfassend Zugeben einer bekannten Menge einer Referenznu-

EP 1 427 860 B1

cleinsäure zu dem festen Träger.

5. Verfahren gemäß einem der Ansprüche 1 bis 4, wobei der Teil die Gesamte der wenigstens einen Probe umfasst.
- 5 6. Verfahren gemäß Anspruch 3 oder 4, wobei der Teil eine der Proben umfasst.
7. Verfahren gemäß einem der Ansprüche 1 bis 6, wobei die Nucleinsäure RNA umfasst.
8. Verfahren gemäß Anspruch 7, wobei die RNA mitochondriale RNA, virale RNA und/oder Messenger-RNA umfasst.
- 10 9. Verfahren gemäß einem der Ansprüche 1 bis 8, wobei virale Nucleinsäure detektiert wird.
10. Verfahren gemäß Anspruch 9, wobei die virale Nucleinsäure eine retrovirale Nucleinsäure umfasst.
- 15 11. Verfahren gemäß Anspruch 9 oder 10, wobei die virale Nucleinsäure HIV und/oder HTLV umfasst.
12. Verfahren gemäß einem der Ansprüche 9 bis 11, wobei die virale Nucleinsäure HIV-1 umfasst.
13. Verfahren gemäß einem der Ansprüche 1 bis 12, wobei der Träger ein Filterpapier umfasst.
- 20 14. Verfahren gemäß einem der Ansprüche 1 bis 13, das ein Genotypisieren einer Mutante umfasst.
15. Verfahren gemäß einem der Ansprüche 1 bis 14, wobei die Probe einen Tropfen Vollblut aus einer Finger- oder Fersenpunktion umfasst.
- 25 16. Verfahren gemäß Anspruch 15, wobei die Amplifikation eine Echtzeit-überwachte Amplifikation umfasst.
17. Verfahren gemäß einem der Ansprüche 1 bis 16, wobei die Nucleinsäuredetektion und/oder -quantifizierung mit einem Endpunkt-Ablese-System durchgeführt wird.
- 30 18. Verfahren gemäß einem der Ansprüche 1 bis 17, wobei ein Verhältnis zwischen verschiedenen Nucleinsäuren bestimmt wird.

35 **Revendications**

1. Un procédé pour quantifier un acide nucléique d'intérêt dans, au moins, un échantillon sanguin comprenant :
 - 40 - l'administration dudit échantillon à un support solide capable d'absorber au moins en partie ledit échantillon, de façon à obtenir au moins une tache;
 - le séchage dudit support;
 - la découpe d'au moins une tache dudit support solide, ladite au moins une tache comprenant au moins 250µl d'échantillon;
 - 45 - l'administration de ladite au moins une tache sur un tampon de lyse chaotropique pour l'isolation de l'acide nucléique de sorte que l'acide nucléique soit extrait dudit support;
 - la purification additionnelle de l'acide nucléique présent dans ledit tampon de lyse;
 - la réalisation d'une étape d'amplification d'un acide nucléique; et
 - la quantification dudit acide nucléique d'intérêt.
- 50 2. Un procédé selon la revendication 1 comprenant l'identification dudit acide nucléique.
3. Un procédé selon une quelconque des revendications 1-2, dans lequel ledit support solide comporte au moins deux échantillons.
- 55 4. Un procédé selon une quelconque des revendications 1-3, comprenant l'administration audit support solide d'une quantité connue d'un acide nucléique de référence.
5. Un procédé selon une quelconque des revendications 1-4, dans lequel ladite partie comprend l'ensemble dudit au

EP 1 427 860 B1

moins un échantillon.

6. Un procédé selon l'une des revendications 3 ou 4, dans lequel ladite partie comprend un desdits échantillons.

5 7. Un procédé selon une quelconque des revendications 1-6, dans lequel ledit acide nucléique comprend de l'ARN.

8. Un procédé selon la revendication 7, dans lequel ledit ARN comprend un ARN mitochondrial, un ARN viral et/ou un ARN messager.

10 9. Un procédé selon une quelconque des revendications 1-8, dans lequel est détecté de l'acide nucléique viral.

10. Un procédé selon la revendication 9, dans lequel ledit acide nucléique viral comprend un acide nucléique rétroviral.

11. Un procédé selon la revendication 9 ou 10, dans lequel ledit acide nucléique viral comprend le VIH et/ou le HTLV.

15 12. Un procédé selon une quelconque des revendications 9-11, dans lequel l'acide nucléique viral comprend le VIH-1.

13. Un procédé selon une quelconque des revendications 1-12, dans lequel ledit support comprend un filtre en papier.

20 14. Un procédé selon une quelconque des revendications 1-13, comprenant le génotypage d'un mutant.

15. Un procédé selon une quelconque des revendications 1-14, dans lequel ledit échantillon comprend une gouttelette de sang total prélevée sur un doigt ou ponctionnée au talon.

25 16. Un procédé selon la revendication 15, dans lequel ladite amplification comprend une amplification contrôlée en temps réel.

17. Un procédé selon une quelconque des revendications 1-16, dans lequel la détection de l'acide nucléique et/ou sa quantification est réalisée avec un système de lecture du point de virage.

30 18. Un procédé selon une quelconque des revendications 1-17, dans lequel est déterminé un ratio entre différents acides nucléiques.

35

40

45

50

55




Fig. 1




Fig. 2

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5139742 A [0008] [0035]

Non-patent literature cited in the description

- **Boom R ; Sol CJ ; Salimans MM ; Jansen CL ; Wertheim-van Dillen PM ; van der Noordaa J.** Rapid and simple method for purification of nucleic acids. *J Clin Microbiol*, 1990, vol. 28 (3), 495-503 [0061]
- **Baar MP ; van Dooren MW ; de Rooij E ; Bakker M ; van Gemen B ; Goudsmit J ; Ronde A.** Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. *J Clin Microbiol.*, April 2001, vol. 39 (4), 1378-84 [0061]
- **Baar MP ; Timmermans EC ; Bakker M ; Rooij E ; van Gemen B ; Goudsmit J.** One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. *J Clin Microbiol.*, May 2001, vol. 39 (5), 1895-902 [0061]
- **Caggana M ; Conroy J ; Pass K.** Rapid, efficient method for multiplex amplification from filter paper. *Human mutation*, 1998, vol. 11, 404-409 [0061]
- **Rompanen E ; Mononen I.** PCR-oligonucleotide ligation assay from dried blood spots. *Clinical Chemistry*, 1999, vol. 45 (11), 2022-2025 [0061]
- **Rompanen E.** Oligonucleotide ligation assay: applications to molecular diagnosis of inherited disorders. *Scand J Clin Lab Invest*, 2001, vol. 61, 123-130 [0061]
- **Tzeng CC ; Lin SJ ; Chen YJ ; Kuo PL ; Jong YJ ; Tsai LP ; Chen RM.** An effective strategy of using molecular testing to screen mentally retarded individuals for fragile X syndrome. *Diagnostic Molecular Pathology*, 2001, vol. 10, 34-40 [0061]

专利名称(译)	储存和定量施用于固体载体的核酸		
公开(公告)号	EP1427860B1	公开(公告)日	2009-06-17
申请号	EP2003738785	申请日	2003-07-03
[标]申请(专利权)人(译)	普里马根控股公司		
申请(专利权)人(译)	PRIMAGEN HOLDING BV公司		
当前申请(专利权)人(译)	PRIMAGEN HOLDING BV公司		
[标]发明人	DE ROOIJ ESTHER REGINA DE BAAR MARINUS PETRUS		
发明人	DE ROOIJ, ESTHER, REGINA DE BAAR, MARINUS, PETRUS		
IPC分类号	C12Q1/68 G01N33/53 C12M1/00 C12N15/09 C12Q1/70 G01N33/569		
CPC分类号	C12Q1/6806 C12Q1/703 C12Q2545/114 C12Q2565/518		
优先权	2002077697 2002-07-04 EP		
其他公开文献	EP1427860A2		
外部链接	Espacenet		

摘要(译)

本发明提供了一种检测至少一种样品中目标核酸的方法，包括将所述样品给予能够至少部分吸收所述样品的固体载体，干燥所述载体，至少提供所述载体的代表性部分。核酸分离溶液，以便从所述载体中提取代表性量的所述核酸，并检测所述代表性量的所述核酸。采用本发明的方法，样品，例如体液样品，以这样的方式稳定，使得它可以从服用部位（例如当地医院或欠发达国家的实验室）运送并被送到通过正常的物流手段在世界其他地方建立服务测试实验室。优选向所述载体施用至少100μl，更优选至少250μl样品，以检测低滴度的目标核酸。还提供了用于检测，鉴定和/或定量样品中感兴趣的核酸的试剂盒，其包含能够至少部分吸收所述样品的固体载体，和核酸分离溶液。




Fig. 1